Beclomethasone Dipropionate
| Evidence Level: L3 | Predicted Indications: 1 |
Table of Contents
- Beclomethasone Dipropionate
- Pharmacist Assessment Report
- Beclomethasone Dipropionate: From Asthma and Allergic Rhinitis to Atopic Eczema
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Canada Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Beclomethasone Dipropionate: From Asthma and Allergic Rhinitis to Atopic Eczema
One-Sentence Summary
Beclomethasone dipropionate is a glucocorticoid originally used to treat asthma and allergic rhinitis (including vasomotor rhinitis and nasal polyps). The TxGNN model predicts it may be effective for atopic eczema, but currently there are no registered clinical trials and only 9 publications, mostly reviews, small clinical studies and safety or formulation studies, supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Asthma, allergic rhinitis (including intrinsic and allergic asthma, vasomotor rhinitis, nasal polyps) |
| Predicted New Indication | Atopic eczema |
| TxGNN Prediction Score | 0.9941 |
| Evidence Level | L3 |
| Canada Market Status | Marketed (marketed DINs: 5 of 5) |
| Number of DINs | 5 (marketed: 5) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on known pharmacology, beclomethasone dipropionate is a glucocorticoid prodrug. It is hydrolysed to its active 17-monopropionate form, which acts through the glucocorticoid receptor to suppress pro-inflammatory cytokines and Th2-driven allergic inflammation.
This is the same inflammatory pathway that underlies its established use in asthma and allergic rhinitis. Atopic eczema shares the atopic, Th2-type phenotype, so the mechanistic link is plausible. Topical corticosteroids are already a standard class of therapy for atopic dermatitis. The open question is therefore not whether the drug class works, but the specific benefit-risk balance of beclomethasone dipropionate (for example, in oral or topical form) compared with existing options.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 14522624 | 2003 | Clinical study | J Dermatol Treat | Short-term growth and bone turnover in 8 children using occlusive steroid “wet-wrap” dressings for atopic eczema (safety focus) |
| 1476023 | 1992 | Clinical study (small series) | Acta Derm Venereol Suppl | Oral beclomethasone dipropionate in difficult childhood atopic dermatitis: stable control in 10/14 patients, but evidence of slowed linear growth and effects on adrenal function |
| 374799 | 1979 | Comparative clinical study | Nihon Hifuka Gakkai Zasshi | Systemic effects of topical beclomethasone dipropionate compared with betamethasone valerate and fluocinonide (safety focus) |
| 19571596 | 2009 | Review | Neuroimmunomodulation | Intranasal corticosteroids and adrenal suppression in patients with allergic rhinitis, asthma and atopic dermatitis |
| 11488426 | 2001 | Review | Jpn J Pharmacol | Overview of drugs for allergic diseases; inhaled beclomethasone dipropionate and fluticasone are rapidly degraded after absorption |
| 14616123 | 2003 | Review | Allergy | Corticosteroid allergy in asthma (delayed contact allergy and occasional immediate allergy) |
| 7813169 | 1994 | Review | Clin Ter | Allergy drugs in pregnancy (indirect relevance) |
| 30911861 | 2019 | Preclinical / formulation | AAPS PharmSciTech | Beclomethasone dipropionate micelles in a hydrogel tested in a sub-chronic dermatitis animal model |
| 8765824 | 1996 | In vitro study | J Allergy Clin Immunol | Topical steroids enhanced spontaneous IgE production in vitro in atopic dermatitis patients (a potentially adverse signal) |
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02089602 | PROPADERM | Not specified | Not specified |
| 02172712 | MYLAN-BECLO AQ | Not specified | Not specified |
| 02242030 | QVAR | Not specified | Not specified |
| 02238796 | APO-BECLOMETHASONE NASAL SPRAY | Not specified | Not specified |
| 02242029 | QVAR | Not specified | Not specified |
Safety Considerations
Contraindications flagged in the knowledge graph (these come from drug-disease relationships, not from package insert text): liver disease, gallbladder disease, measles, herpes simplex keratitis, adrenocortical insufficiency, Addison disease, varicella zoster infection, fungal infections, dermatophytosis, ocular hypertension, glaucoma, parasitic infection, infectious disease in general, mycobacterial infection, leprosy, and diseases of the lower respiratory tract, upper respiratory tract, paranasal sinuses and nasal cavity.
Drug Interactions: 49 interactions were identified. The first 20 listed include:
- Major: Desmopressin
- Moderate: Acetazolamide, foscarnet, loop diuretics (furosemide, bumetanide), thiazide-type diuretics (hydrochlorothiazide, bendroflumethiazide, benzthiazide, chlorothiazide, chlorthalidone), amphotericin B (including lipid complex, cholesteryl sulfate and liposomal forms), capreomycin, cisplatin, diclofenamide
- Minor: Formoterol, salbutamol, arformoterol
Safety signals in the literature: Studies of corticosteroid use in atopic dermatitis report slowed linear growth and effects on adrenal function in children (oral use), and adrenal suppression with intranasal use. Local or systemic corticosteroid allergy has also been described.
Package insert warnings and contraindications were not available for this report; please refer to the Health Canada package insert.
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanistic plausibility is high and the TxGNN score is strong (0.9941). However, there are no registered clinical trials, and the literature consists of reviews, small or older studies, and safety or formulation work, with no controlled efficacy data for atopic eczema. Topical corticosteroids are already standard therapy, so a specific advantage of beclomethasone dipropionate has not been shown. The package insert safety review, which is needed for safety screening, is also still outstanding.
To proceed, the following is needed:
- Health Canada package insert warnings and contraindications (blocking for safety screening)
- Mechanism of action data from DrugBank
- Controlled efficacy data, or a head-to-head comparison against established topical corticosteroids in atopic eczema
- Choice of formulation and route (oral versus topical) with a benefit-risk assessment, especially for children (growth and adrenal suppression)
- Approved indication text and dosage forms for the Canadian licences, to confirm which products and routes are relevant
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.